Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 149

Sort by

Sort Order Select

Journal Articles

Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents

Caroline Diorio, Laura Hernandez-Miyares, Diego A. Espinoza, Brenda L. Banwell, Amit Bar-Or, Amanda M. DiNofia, Allison Barz Leahy, Zachary Martinez, Regina M. Myers, Sarah E. Hopkins, Susan R. Rheingold, David T. Teachey, Angela N. Viaene, Lisa M. Wray, Shannon L. Maude, Stephan A. Grupp, Jennifer L. McGuire

Blood (2024) 144 (13): 1387–1398.

https://doi.org/10.1182/blood.2024023933

Published: 2024

Includes: Supplemental data

Journal Articles

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Blood (2024) 144 (9): 1010–1021.

https://doi.org/10.1182/blood.2024025106

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy

Blood (2023) 141 (6): 609–619.

https://doi.org/10.1182/blood.2022017866

Published: 2023

Includes: Supplemental data

Journal Articles

CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Blood (2022) 140 (Supplement 1): 2376–2377.

https://doi.org/10.1182/blood-2022-168139

Published: 2022

Journal Articles

Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway

Caroline Diorio, Tiffaney L. Vincent, Tori Fuller, Rawan Shraim, Tina Glisovic-Aplenc, Theresa Ryan, Kimberly Veliz, Haley Newman, Gerald Wertheim, Hamid Bassiri, Annette Vu, Michael Hogarty, Carl H June, Stephan A. Grupp, Sarah K Tasian, Richard Aplenc, Saar Gill, David T. Teachey

Blood (2022) 140 (Supplement 1): 10285–10286.

https://doi.org/10.1182/blood-2022-167893

Published: 2022

Journal Articles

Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL

Blood (2022) 140 (6): 619–629.

https://doi.org/10.1182/blood.2022015825

Published: 2022

Includes: Supplemental data

Journal Articles

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

Allison Barz Leahy, Kaitlin J. Devine, Yimei Li, Hongyan Liu, Regina Myers, Amanda DiNofia, Lisa Wray, Susan R. Rheingold, Colleen Callahan, Diane Baniewicz, Maria Patino, Haley Newman, Stephen P. Hunger, Stephan A. Grupp, David M. Barrett, Shannon L. Maude

Blood (2022) 139 (14): 2173–2185.

https://doi.org/10.1182/blood.2021012727

Published: 2022

Includes: Supplemental data

Journal Articles

Ex Vivo T-Cell Receptor αβ + /CD19 + depletion of Peripheral Stem Cell Grafts for Pediatric Patients with Bone Marrow Failure (BMF) Undergoing Unrelated Donor Transplantation

Joseph H Oved, Caitlin W Elgarten, Yongping Wang, Stephan Kadauke, Dimitri S. Monos, David M. Barrett, Stephan A. Grupp, Nancy Bunin, Timothy S. Olson

Blood (2021) 138 (Supplement 1): 171.

https://doi.org/10.1182/blood-2021-154305

Published: 2021

Journal Articles

Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19

Blood (2021) 138 (Supplement 1): 167.

https://doi.org/10.1182/blood-2021-149477

Published: 2021

Journal Articles

Complete Versus Incomplete Hematologic Recovery after CAR T Cell Therapy: Implications for Relapse Free Survival and Overall Survival in Pediatric and Young Adult Patients with Relapsed/Refractory B-ALL

Benjamin J Lerman, Yimei Li, Hongyan Liu, Regina M. Myers, Kaitlin Devine, Colleen Callahan, Diane Baniewicz, Stephan Kadauke, Amanda M. DiNofia, Susan R. Rheingold, Lisa Wray, Richard Aplenc, Stephan A. Grupp, Shannon L. Maude, Allison Barz Leahy

Blood (2021) 138 (Supplement 1): 1747.

https://doi.org/10.1182/blood-2021-151114

Published: 2021

Journal Articles

Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors

Sherly Mardiana, Olga Shestova, Stephan A. Grupp, Marco Ruella, David M. Barrett, Saar Gill

Blood (2021) 138 (Supplement 1): 1727.

https://doi.org/10.1182/blood-2021-146995

Published: 2021

Journal Articles

Prognostic Value of Elafin in Acute Graft-Versus-Host Disease

Blood (2021) 138 (Supplement 1): 3900.

https://doi.org/10.1182/blood-2021-154302

Published: 2021

Journal Articles

Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Regina M. Myers, Kaitlin Devine, Yimei Li, Sophie Lawrence, Allison Barz Leahy, Hongyan Liu, Lauren Vernau, Colleen Callahan, Diane Baniewicz, Stephan Kadauke, Regina McGuire, Margaret A Cameron, Amanda M. DiNofia, Susan R. Rheingold, Richard Aplenc, Carl H June, Stephan A. Grupp, Lisa Wray, Shannon L. Maude

Blood (2021) 138 (Supplement 1): 474.

https://doi.org/10.1182/blood-2021-147299

Published: 2021

Journal Articles

A Phase 3, Randomized, Adaptive Study of Defibrotide (DF) Vs Best Supportive Care (BSC) for the Prevention of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) in Patients (pts) Undergoing Hematopoietic Cell Transplantation (HCT): Preliminary Results

Stephan A. Grupp, Selim Corbacioglu, Hyoung Jin Kang, Takanori Teshima, Michelle Zanette, Paty Lopez, Vian Amber, Antonio Pagliuca, Paul G. Richardson

Blood (2021) 138 (Supplement 1): 749.

https://doi.org/10.1182/blood-2021-147284

Published: 2021

Journal Articles

Ikaros Mediates Antigen Escape Following CD19 CAR T Cell Therapy in r/r B-ALL

Pablo Domizi, Jolanda Sarno, Astraea Jager, Reema Baskar, Warren D. Reynolds, Bita Sahaf, Sean Bendall, Charles G. Mullighan, Allison Barz Leahy, Regina M. Myers, Stephan A. Grupp, Elena Sotillo, David Barrett, Kara L. Davis

Blood (2021) 138 (Supplement 1): 613.

https://doi.org/10.1182/blood-2021-151002

Published: 2021

Journal Articles

Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Samuel John, Michael A. Pulsipher, Amy Moskop, Zhen-Huan Hu, Christine L. Phillips, Erin Marie Hall, Steven P. Margossian, Sarah Nikiforow, Paul L. Martin, Benjamin Oshrine, Amy K. Keating, Rayne H. Rouce, Ranjan Tiwari, Santiago Redondo, Jennifer Willert, Abhijit Agarwal, Marcelo C Pasquini, Stephan A. Grupp

Blood (2021) 138 (Supplement 1): 428.

https://doi.org/10.1182/blood-2021-146393

Published: 2021

Journal Articles

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 256.

https://doi.org/10.1182/blood-2021-153336

Published: 2021

Journal Articles

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

Natalie F. Uy, MD, Edward Pequignot, Noelle V. Frey, MD, Megan Davis, PhD, Elizabeth O. Hexner, MD, Stephen J. Schuster, MD, Saar Gill, MD PhD, Alison W. Loren, MD, Stephan A Grupp, MD PhD, J. Joseph Melenhorst, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Joan Gilmore, BS, Lester Lledo, RN,NP, Wei-Ting Hwang, PhD, Don L. Siegel, MD PhD, Bruce L Levine, PhD, Carl H June, MD, David L. Porter, MD

Blood (2020) 136 (Supplement 1): 30–32.

https://doi.org/10.1182/blood-2020-141224

Published: 2020

Journal Articles

HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia

Michael W Boyer, MD, Sonali Chaudhury, MBBS,MD, Kara L Davis, DO, Timothy Alan Driscoll, MD, Stephan A Grupp, MD PhD, Michelle Hermiston, MD PhD, Samuel John, MD, Amy K Keating, MD PhD, Christina Kovacs, BS, JD, Andrea Magley, BS, Gary Douglas Myers, MD, Christine L Phillips, MD, Michael A Pulsipher, MD, Das Purkayastha, PhD, Julie-An Talano, MD, Jennifer Willert, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136340

Published: 2020

Journal Articles

Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-139575

Published: 2020

NARROW

Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy

CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway

Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

Ex Vivo T-Cell Receptor αβ + /CD19 + depletion of Peripheral Stem Cell Grafts for Pediatric Patients with Bone Marrow Failure (BMF) Undergoing Unrelated Donor Transplantation

Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19

Complete Versus Incomplete Hematologic Recovery after CAR T Cell Therapy: Implications for Relapse Free Survival and Overall Survival in Pediatric and Young Adult Patients with Relapsed/Refractory B-ALL

Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors

Prognostic Value of Elafin in Acute Graft-Versus-Host Disease

Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

A Phase 3, Randomized, Adaptive Study of Defibrotide (DF) Vs Best Supportive Care (BSC) for the Prevention of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) in Patients (pts) Undergoing Hematopoietic Cell Transplantation (HCT): Preliminary Results

Ikaros Mediates Antigen Escape Following CD19 CAR T Cell Therapy in r/r B-ALL

Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia

Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only